## Alexa Fluor® 647 anti-human CD16

Catalog # / Size: 2110115 / 25 tests

2110100 / 100 tests

Clone: 3G8

**Isotype:** Mouse IgG1, κ

Immunogen: Human PMN cells

Reactivity: Human

**Preparation:** The antibody was purified by affinity

chromatography, and conjugated with

Alexa Fluor® 647 under optimal

conditions.


Formulation: Phosphate-buffered solution, pH 7.2,

containing 0.09% sodium azide and

0.2% (w/v) BSA (origin USA).

Workshop Number: V NK80

Concentration: Lot-specific



Human peripheral blood lymphocytes stained with 3G8 Alexa Fluor® 647

## **Applications:**

**Applications:** Flow Cytometry

Recommended

**Usage:** 

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

\* Alexa Fluor® 647 has a maximum emission of 668 nm when it is excited at 633nm / 635nm.

Application Notes:

The 3G8 antibody blocks neutrophil phagocytosis and stimulates NK cell proliferation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections<sup>6</sup>, immunoprecipitation3, stimulation of NK cell proliferation4, blocking of phagocytosis5, and blocking of immunoglobulin binding to FcyRIII<sup>7,8</sup>. The LEAF purified antibody (Endotoxin <0.1 EU/ $\mu$ g, Azide-Free, 0.2  $\mu$ m filtered) is recommended for functional assays (Cat. No. 302014). For highly sensitive assays, we recommend Ultra-LEAF purified antibody (Cat. No. 302050) with a lower endotoxin limit than standard LEAF purified antibodies (Endotoxin <0.01 EU/microg).

Application References:

1. Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York.

2. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.

3. Edberg J, et al. 1997. J. Immunol. 159:3849. (IP)

4. Hoshino S, et al. 1991. Blood 78:3232. (Stim)

5. Tamm A, et al. 1996. Immunol. 157:1576. (Block)

6. Da Silva DM, et al. 2001. Int. Immunol. 13:633. (IHC)

7. Holl V, et al. 2004. J. Immunol. 173:6274. (Block)

8. Hober D, et al. 2002. J. Gen. Virol. 83:2169. (Block)

9. Brainard DM, et al. 2009. J. Virol. 83:7305. PubMed

10. Smed-Sörensen A, et al. 2008. Blood 111:5037. (Block) PubMed

- 11. Timmerman KL, et al. 2008. J. Leukoc. Biol. 84:1271. (FC) PubMed
- 12. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
- 13. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
- 14. Kim WK, et al. 2006. Am. J. Pathol. 168:822. (FC)
- 15. Boltz A, et al. 2011. J. Biol Chem. 286:21896. PubMed
- 16. Wu Z, et al. 2013. J. Virol. 87:7717. PubMed

## **Description:**

CD16 is known as low affinity IgG receptor III (Fc $\gamma$ RIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (Fc $\gamma$ RIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (Fc $\gamma$ RIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC).

## Antigen References:

- 1. Fleit H, et al. 1982. P. Natl. Acad. Sci. USA 79:3275.
- 2. Stroncek D, et al. 1991. Blood 77:1572.
- 3. Wirthmueller U, et al. 1992. J. Exp. Med. 175:1381.